- Home
- URGN vs ORGO Comparison
URGN vs ORGO Comparison
Compare URGN & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- ORGO
- Stock Information
- Founded
- URGN 2004
- ORGO 1985
- Country
- URGN United States
- ORGO United States
- Employees
- URGN N/A
- ORGO N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- URGN Health Care
- ORGO Health Care
- Exchange
- URGN Nasdaq
- ORGO Nasdaq
- Market Cap
- URGN 465.9M
- ORGO 459.5M
- IPO Year
- URGN 2017
- ORGO N/A
- Fundamental
- Price
- URGN $10.08
- ORGO $3.21
- Analyst Decision
- URGN Strong Buy
- ORGO Strong Buy
- Analyst Count
- URGN 6
- ORGO 2
- Target Price
- URGN $42.25
- ORGO $5.00
- AVG Volume (30 Days)
- URGN 308.1K
- ORGO 387.6K
- Earning Date
- URGN 03-13-2025
- ORGO 02-27-2025
- Dividend Yield
- URGN N/A
- ORGO N/A
- EPS Growth
- URGN N/A
- ORGO N/A
- EPS
- URGN N/A
- ORGO N/A
- Revenue
- URGN $89,363,000.00
- ORGO $455,038,000.00
- Revenue This Year
- URGN $12.17
- ORGO $9.65
- Revenue Next Year
- URGN $44.23
- ORGO $1.57
- P/E Ratio
- URGN N/A
- ORGO N/A
- Revenue Growth
- URGN 15.64
- ORGO 1.34
- 52 Week Low
- URGN $9.78
- ORGO $2.17
- 52 Week High
- URGN $20.70
- ORGO $4.57
- Technical
- Relative Strength Index (RSI)
- URGN 40.55
- ORGO 38.78
- Support Level
- URGN $9.86
- ORGO $3.42
- Resistance Level
- URGN $11.87
- ORGO $3.78
- Average True Range (ATR)
- URGN 0.50
- ORGO 0.15
- MACD
- URGN -0.04
- ORGO -0.04
- Stochastic Oscillator
- URGN 10.95
- ORGO 1.72
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.